^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Solid Tumor
    Drug:Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) +
    AiRuiKang (dalpiciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

    Excerpt:
    ...- HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline)....
    Trial ID:
    DAP-Her-01
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

    Excerpt:
    ......
    Trial ID:
    PLEASURABLE
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

    Excerpt:
    ...- HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline)....
    Trial ID:
    NCT03993964
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer

    Excerpt:
    ...- Patients definitely diagnosed by pathology as Her2 positive stage III/IV gastric cancer...
    Trial ID:
    SHR6390-Id
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A single-arm, double-cohort, prospective, open-label, phase II exploratory study evaluating dalpiciclib combined with pyrotinib maleate in first-line treatment of HER2+ advanced breast cancer

    Excerpt:
    ...Follow the 2018 ASCO-CAP HER2 positive Interpretation guidelines. ...
    Trial ID:
    ChiCTR2200058979
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2 positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial

    Published date:
    05/19/2021
    Excerpt:
    pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2 positive gastric cancer or solid tumors (NCT03480256)...19 pts (14 gastric cancer, 3 colorectal cancer, 2 other solid tumors) were enrolled...overall response rate was 38.9%, with 7 PR (A: n = 3; E: n = 2; F: n = 2) and 7 SD. The median PFS was 3.83 months, with 2 pts received treatment over 12 months (A: n = 1; F: n = 1). Pyrotinib combined with SHR6390 had shown acceptable safety profile and encouraging efficacy in refractory advanced HER2 positive solid tumors.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e16009
    Trial ID:
    SHR6390-Id